This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs; Ivermectin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Merck Research Laboratories, Division of Merck & Co., Inc. The supplement provides for subcutaneous use of ivermectin injection as an anti-parasitic in ranch-raised foxes.

EFFECTIVE DATE: August 30, 1995.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20857, 301-594-1643.

SUPPLEMENTARY INFORMATION: Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, NJ 07065, is sponsor of NADA 128-409 which provides for the use of 0.27 percent ivermectin as an anti-parasitic for treatment and control of parasitism.

For in-ranch use only. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


Stephen F. Sundlof,
Director, Center for Veterinary Medicine.

[FR Doc. 95-21454 Filed 8-29-95; 8:45 am]

BILLING CODE 4160-01-F

21 CFR Part 529

Certain Other Dosage Form New Animal Drugs; Gentamicin Sulfate Intrauterine Solution

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Macleod Pharmaceuticals, Inc. The ANADA provides for the use of a generic gentamicin solution for control of bacterial infections of the uterus (metritis) of horses and as an aid in improving conception in mares with uterine infections caused by bacteria sensitive to gentamicin.

EFFECTIVE DATE: August 30, 1995.

FOR FURTHER INFORMATION CONTACT: Sandra K. Woods, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20857, 301-594-1612.
SUPPLEMENTARY INFORMATION: Macleod Pharmaceuticals, Inc., 2600 Canton Ct., Fort Collins, CO 80525, is the sponsor of ANADA 200–115, which provides for the use of a generic gentamicin solution (100 milligrams/milliliter [mg/mL]) for control of bacterial infections of the uterus (metritis) in horses and as an aid in improving conception in mares with uterine infections caused by bacteria sensitive to gentamicin.

Approval of ANADA 200–115 for Macleod Pharmaceuticals’ gentamicin sulfate solution (100 mg/mL gentamicin) is as a generic copy of Schering’s Gentocin® Solution (100mg/mL gentamicin) in NADA 046724. The ANADA is approved as of July 21, 1995, and the regulations are amended in 21 CFR 529.1044a to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and § 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency’s finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects in 21 CFR Part 529

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 529 is amended as follows:

PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 529 continues to read as follows:


§ 529.1044a [Amended]

2. Section 529.1044a Gentamicin sulfate intrauterine solution is amended in paragraph (b) by removing “000061, 057561, and 000856” and adding in its place “000061, 000856, 057561, and 058711”.


Stephen F. Sundlof,
Director, Center for Veterinary Medicine.

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Community Planning and Development

24 CFR Part 91

[Docket No. FR 3611–F–10]

Consolidated Submission for Community Planning and Development Programs

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Final rule.

SUMMARY: As part of HUD’s effort to consolidate and streamline submission requirements for the four formula grant programs, the Department published in the Federal Register on January 5, 1995, a final rule that consolidated into a single submission the planning and application aspects of the Department’s Community Development Block Grant (CDBG), Emergency Shelter Grant (ESG), HOME Investment Partnerships (HOME), and Housing Opportunities for Persons with AIDS (HOPWA) programs. The purpose of this rule is to make an amendment to the deadline for submission of the Consolidated Plan in order to receive Community Development Block Grant funds.


FEDERAL REGISTER [FR Doc. 95–21455 Filed 8–29–95; 8:45 am]
BILLING CODE 4160–01–F

DEPARTMENT’S COMMUNITY DEVELOPMENT BLOCK GRANT

Office of the Assistant Secretary for Community Planning and Development

24 CFR Part 91

[Docket No. FR 3611–F–10]

Consolidated Submission for Community Planning and Development Programs

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Final rule.

SUMMARY: As part of HUD’s effort to consolidate and streamline submission requirements for the four formula grant programs, the Department published in the Federal Register on January 5, 1995, a final rule that consolidated into a single submission the planning and application aspects of the Department’s Community Development Block Grant (CDBG), Emergency Shelter Grant (ESG), HOME Investment Partnerships (HOME), and Housing Opportunities for Persons with AIDS (HOPWA) programs. The purpose of this rule is to make an amendment to the deadline for submission of the Consolidated Plan in order to receive Community Development Block Grant funds.

The regulation requires jurisdictions to align the program years for the four formula programs and to submit the Consolidated Plan 45 days before the start of the program year instead of the 30 days previously recommended for submission of the CDBG Final Statement. The final date for submission of all Consolidated Plans was established as August 16. The date previously established for submission of all CDBG final statements had been the first working day in September. To provide maximum flexibility during this transition period, HUD is amending the Consolidated Plan rule to permit the submission of the Consolidated Plan for Fiscal Year 1995 to be made not later than September 30, 1995.

JUSTIFICATION FOR FINAL RULEMAKING

HUD generally publishes a rule for public comment before issuing a rule for effect, in accordance with its own regulations on rulemaking at 24 CFR part 10. However, part 10 provides that prior public procedure will be omitted if HUD determines that it is “impracticable, unnecessary, or contrary to the public interest” (24 CFR 10.1).

In this case, HUD finds that publishing this rule providing for a new consolidated plan deadline for FY 1995 for public comment would be impracticable and contrary to the public interest. Maximum flexibility in submitting consolidated plans during this first year of transition following publication of the final rule establishing the consolidated plan is in the public interest. The time necessary to allow for public comment would preclude the possibility of making the rule effective before the extended deadline date of September 30, 1995. It would be impracticable, therefore, to extend greater flexibility to grantees if a public comment period was provided before the rule takes effect.

OTHER MATTERS

Executive Order 12866

This final rule was reviewed by the Office of Management and Budget (OMB) under Executive Order 12866 on Regulatory Planning and Review, issued by the President on September 30, 1993.